2018’s Top Ten Drugs
Humira, AbbVie’s TNF inhibitor, will lead the pack again in 2018 with an expected $20 B in sales, the first drug to ever pass that threshold. It will more than double the sales of Revlimid which holds the number two spot at $9.2 B in sales. Not surprisingly, five of the top ten spots belong to cancer treatments and the remaining are medications for diseases of the retina, auto immune disease and a blood clots.
For more information on how we can help you with your pharmacy solutions, please contact us today!